Efracea
Efracea contains doxycycline, an antibacterial that has been shown to inhibit neutrophil activity and several pro-inflammatory reactions, including those associated with phospholipase A2, endogenous nitric oxide and interleukin-6. It works by altering the pathophysiology of the inflammatory lesions of rosacea that is, in part, a manifestation of a neutrophil-mediated process. The OD 40mg modified release is designed to stay below the antimicrobial threshold to reduce commonly occurring side effects, while retaining an anti-inflammatory action